Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Capecitabine
Drug ID BADD_D00349
Description Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Indications and Usage For the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen. May also be used in combination with docetaxel for the treatment of metastatic breast cancer in patients who have failed to respond to, or recurred or relasped during or following anthracycline-containing chemotherapy. Capecitabine is used alone as an adjuvant therapy following the complete resection of primary tumor in patients with stage III colon cancer when monotherapy with fluroprymidine is preferred. The use or capecitabine in combination regimens for advanced gastric cancer is currently being investigated.
Marketing Status approved; investigational
ATC Code L01BC06
DrugBank ID DB01101
KEGG ID D01223
MeSH ID D000069287
PubChem ID 60953
TTD Drug ID D00HCQ
NDC Product Code 55111-893; 82920-001; 72205-007; 72485-205; 62331-043; 16714-467; 51407-640; 55111-496; 55111-497; 61269-475; 65162-844; 15308-0714; 54893-0002; 59651-205; 64980-277; 70756-815; 68001-487; 69097-949; 72205-006; 63482-099; 72969-094; 16729-072; 59923-721; 61269-470; 0054-0271; 69539-019; 0093-7473; 64980-276; 0054-0272; 69097-948; 72606-554; 53104-7618; 55512-0015; 0004-1100; 51407-639; 67877-459; 68001-488; 69539-020; 35369-0010; 16729-073; 51407-096; 62756-238; 62756-239; 65162-843; 67877-458; 59651-204; 72485-204; 72606-555; 49452-1713; 68554-0033; 0004-1101; 0093-7474; 51407-095; 60687-149; 0378-2511; 70756-816; 53183-4009; 54245-7014; 65129-1241; 81955-0001; 16714-468; 59923-722
UNII 6804DJ8Z9U
Synonyms Capecitabine | N(4)-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine | Xeloda
Chemical Information
Molecular Formula C15H22FN3O6
CAS Registry Number 154361-50-9
SMILES CCCCCOC(=O)NC1=NC(=O)N(C=C1F)C2C(C(C(O2)C)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Megacolon07.02.05.0020.000392%Not Available
Melaena24.07.02.013; 07.12.02.004--Not Available
Melanocytic naevus23.10.01.007; 16.26.01.0070.000448%Not Available
Memory impairment19.20.01.003; 17.03.02.003--
Menopausal symptoms21.02.02.002--Not Available
Mental disability26.01.01.001--Not Available
Mesenteric artery thrombosis07.15.02.008; 24.01.08.0030.000168%Not Available
Metabolic acidosis14.01.01.0030.001511%Not Available
Metastases to liver16.22.02.001; 09.04.02.0040.002574%Not Available
Metastases to lung22.08.01.005; 16.22.02.0020.001612%Not Available
Migraine24.03.05.003; 17.14.02.001--Not Available
Mitral valve incompetence02.07.01.0020.000280%Not Available
Monoplegia17.01.04.0030.000112%Not Available
Mood altered19.04.02.007--Not Available
Mood swings19.04.03.001--Not Available
Morphoea10.04.07.002; 23.03.02.011; 15.06.01.0080.000168%Not Available
Mouth haemorrhage24.07.02.014; 07.05.02.0010.000280%
Mouth ulceration07.05.06.0040.001880%Not Available
Mucosal inflammation08.01.06.0020.017853%Not Available
Mucosal ulceration08.01.06.003--Not Available
Mucous stools07.01.03.0060.000112%Not Available
Muscle spasms15.05.03.004--
Muscular weakness17.05.03.005; 15.05.06.001--
Mutism19.19.01.001; 17.02.08.0070.000112%Not Available
Myalgia15.05.02.001--
Myelopathy17.10.01.0070.000112%Not Available
Myocardial infarction24.04.04.009; 02.02.02.007--
Myocardial ischaemia24.04.04.010; 02.02.02.0080.001287%Not Available
Myocarditis02.04.03.001--
Myoclonus17.02.05.008--Not Available
The 12th Page    First    Pre   12 13 14 15 16    Next   Last    Total 31 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene